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Cyathostomin resistance to moxidectin
and combinations of anthelmintics in Australian
horses
Ghazanfar Abbas1, Abdul Ghafar1, John Hurley2, Jenni Bauquier1, Anne Beasley3, Edwina J. A. Wilkes4,
Caroline Jacobson5, Charles El‑Hage1, Lucy Cudmore6, Peter Carrigan6, Brett Tennent‑Brown1, Charles G. Gauci1,
Martin K. Nielsen7, Kristopher J. Hughes4, Ian Beveridge1 and Abdul Jabbar1*

Abstract
Background: Cyathostomins are the most important and common parasitic nematodes of horses, with > 50 species
known to occur worldwide. The frequent and indiscriminate use of anthelmintics has resulted in the development of
anthelmintic resistance (AR) in horse nematodes. In this study we assessed the efficacy of commonly used anthelmin‑
tics against cyathostomins in Australian thoroughbred horses.
Methods: Two drug efficacy trials per farm were conducted on two thoroughbred horse farms in the state of Victoria,
Australia. In the first trial, the horses on Farm A were treated with single and combinations of anthelmintics, including
oxfendazole (OFZ), abamectin (ABM), abamectin and morantel (ABM + MOR), moxidectin (MOX) and oxfendazole and
pyrantel (OFZ + PYR), at the recommended doses, whereas the horses on Farm B only received MOX, at the recom‑
mended dose. The faecal egg count reduction test (FECRT) was used to determine the efficacy and egg reappear‑
ance period (ERP) of anthelmintics. Based on the results of the first trial, the efficacies of MOX and a combination of
ABM + MOR were reassessed to confirm their activities against cyathostomins.
Results: Of the five anthelmintic products tested on Farm A, resistance against OFZ, ABM and OFZ + PYR was found,
with efficacies of − 41% (− 195% lower confidence limit [LCL]), 73% (60% LCL) and 82% (66% LCL) at 2 weeks posttreatment, respectively. The FECRT showed high efficacies of MOX and ABM + MOR (100%) at 2 week post-treatment
and shortened ERPs for these anthelmintics (ABM + MOR: 4 weeks; MOX: 5 weeks). Resistance to MOX was found on
Farm B, with a reduced efficacy of 90% (70% LCL) and 89% (82% LCL) at 2 weeks post-treatment in trials one and two,
respectively.
Conclusions: This study provides the first evidence of MOX- and multidrug-resistant (ABM and combinations of
anthelmintics) cyathostomins in Australia and indicates the need for continuous surveillance of the efficacy of cur‑
rently effective anthelmintics and large-scale investigations to assess the ERP for various anthelmintics.
Keywords: Australian thoroughbred horses, Cyathostomins, Egg reappearance period, Moxidectin, Resistance, FECRT
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Background
Small strongyles (Strongylida: Cyathostominae), also
known as cyathostomins, are the most important and
common parasitic nematodes of horses, with more than
50 species known to occur worldwide [1, 2]. Cyathostomins have a direct life-cycle, with horses becoming
infected by ingesting third-stage (L3) infective larvae
while grazing and the infective larvae then developing
into adult male and female worms in the large intestine.
The majority of cyathostomin infections are subclinical,
while clinical manifestations of larval cyathostominosis
(i.e. synchronous emergence of fourth-stage larvae from
the intestinal wall) include weight loss, colic, pyrexia,
diarrhea and subcutaneous oedema accompanied by
marked hypoproteinemia, with a case fatality of up to
50% in horses of age ≤ 6 years [3, 4].
Control of cyathostomins in horses has traditionally
relied on interval-based deworming using three classes
of anthelmintics, benzimidazoles (BZs), tetrahydropyrimidines (THPs) and macrocyclic lactones (MLs) [5].
However, the frequent and indiscriminate use of anthelmintics has resulted in the development of anthelmintic resistance (AR) in nematodes infecting horses [5].
Anthelmintic resistance against BZs and THPs is widespread and well-established in cyathostomins, whereas
sporadic accounts of resistance or reduced egg reappearance periods (ERP) against MLs (ivermectin [IVM] and
moxidectin [MOX]) have been reported from various
parts of the world [6–8]. For example, ML resistance in
cyathostomins has been reported either in a single horse
[9] or in a group of horses at the farm level, based on
drug efficacy trials [8, 10–15]. In addition, multiple studies have reported reduced ERP for cyathostomins after
administration of IVM or MOX [11, 13–22].
Due to the growing concern of resistance against individual anthelmintic drugs and/or classes, Barnes et al.
[23] and Leathwick [24] used computer simulation modelling, with the results suggesting that combinations of
≥ 2 anthelmintics with similar nematocidal spectrums
from different classes could delay the development of
resistance. This alternative approach was based on the
successful control of resistant worms of sheep using
combinations of anthelmintics before resistance levels became too high [25, 26]. Although a combination
of anthelmintics is now routinely used in some countries to control horse nematodes, limited information
is available on the efficacy of such anthelmintic regimens against cyathostomins. Kaplan et al. [27] recently
reported > 90%, > 95% and > 99% efficacies of the combination oxibendazole and pyrantel (OBZ + PYR) on 11, 9
and 6 of 11 horse farms, respectively. Notably, the individual efficacies of these drugs were < 90% [27]. Similarly,
in another trial, an additive effect was observed for the
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efficacy of the OBZ + PYR combination against horse
cyathostomins in the first of the four consecutive treatments, whereas the individual efficacies of both drugs
were much lower [28]. In addition, a recent simulationbased study demonstrated that the use of a combination
of anthelmintics could be helpful in delaying the development of AR in cyathostomins, despite one of the active
ingredients exhibiting lower efficacy [29].
Although there are numerous reports of AR and
reduced ERP in cyathostomins of horses from various
parts of the world, little is known about the status of
resistance against MLs, particularly MOX, and combinations of anthelmintics commonly used in Australian
horses. Edward and Hoffmann [9] reported a suspected
case of IVM resistance in cyathostomins based on posttreatment faecal egg counts (FEC). Subsequently, Beasley
et al. [22] reported reduced ERP for MOX (12 weeks) and
IVM (6 weeks) against cyathostomins on one and two
properties, respectively. These findings instigated a regular surveillance of the efficacy and ERP for commonly
used anthelmintics in Australian horses. Therefore, the
aim of this study was to assess the efficacy and ERP of
commonly used anthelmintics on two thoroughbred
horse farms in Australia.

Methods
Selection of horse farms

The following selection criteria were used to enroll the
farms in the study: (i) horses had not been dewormed in
the last 8–10 weeks; (ii) a confirmation that the FEC of
an individual horse was ≥ 45 eggs per gram (EPG) of faeces; and (iii) there was a known history of anthelmintic
usage on the farm in the last 5 years (2015–2020). Horses
selected for the study were assigned to treatment or
control groups using simple randomisation. The control
groups were selected to observe any natural variation in
FECs of untreated horses during the study period.
This study was conducted during 2020–2021 on two
thoroughbred horse farms (designated as A and B) in
the state of Victoria, Australia where resident veterinarians were interested in participating. Farm A is located
200 km north of Melbourne and has approximately 600
horses. Horses of all ages (adults, yearlings and weanlings) are dewormed based on average group FEC (i.e. 10
faecal samples are randomly collected from each paddock
and a FEC is performed on each sample). If the average
EPG of faeces exceeds 500 EPG, all horses in the paddock
are dewormed and the dose of anthelmintic is calculated
according to herd-estimated average body weight in each
age category. IVM and abamectin (ABM) and various
anthelmintic combinations (oxfendazole and pyrantel
[OFZ + PYR] and ABM and morantel [ABM + MOR])
have been used in the last 5 years (2015–2020), while a
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anthelmintics, including OFZ, ABM, MOX, OFZ + PYR
and ABM + MOR at recommended doses while the sixth
group was an untreated control group (Table 1). For MOX,
a formulation with a combination of praziquantel (PZQ)
and MOX was used. Given PZQ has no nematocidal activity, we designated this combination as MOX throughout
the paper. Faecal samples were collected on day 0 (immediately prior to treatment) and then weekly (apart from week
4) until 6 weeks post-treatment (where no resistance was
detected in the second or third weeks). On Farm B, 14 yearlings (aged 12–13 months; male = 3; female = 11) were
selected and randomly divided into two groups (7 animals
in each group). One group was treated with MOX and the
second group was an untreated control group.
Based on the findings of trial 1 on Farm A, the efficacies of MOX and ABM + MOR (Table 1) were re-tested in
15 weanlings (aged 5–6 months; male = 7; female = 8) 8
months after the first trial. For this purpose, the weanlings
were divided into three groups (5 animals in each group),
and two groups were treated with anthelmintics (MOX or
ABM + MOR) while the third group was as an untreated
control group. Similarly, a second trial was conducted on
Farm B in which only the efficacy of MOX was re-tested
in a group of 10 weanlings (aged 7–8 months; male = 3;
female = 7) 9 months after the first trial; the horses were
divided into two groups (5 animals in each group), and one
group was treated with MOX while the second group was
an untreated control group.

combination of ABM and MOR has been used for all age
groups of horses in the last year (2019). Continuous grazing (i.e. set stocking) is used at the farm and horses are
not moved out of the paddocks.
Farm B is located 110 km east of Melbourne and has
approximately 60 thoroughbred horses. Adult horses
on this farm are dewormed based on FEC surveillance: horses with a FEC > 500 EPG are dewormed. On
this farm, young horses are dewormed routinely every
8–10 weeks, with the dose of anthelmintic for an individual horse calculated based on actual body weight. In
the last year (2019), MOX was used to deworm all age
groups of horses. On Farm B, alternate grazing is used,
and horses are periodically moved from one paddock to
the other and replaced with cattle and alpacas.
Anthelmintic treatment and sample collection

Prior to the start of the study, FECs were performed at
both farms to ascertain the worm egg count threshold
required for the study. Anthelmintic dosage was calculated based on the individual horse body weight (Farm B)
or weight of the heaviest animal within a treatment group
(Farm A) and was administered as per the manufacturers’ recommendations. The administration of anthelmintics and the collection of faecal samples (directly from
the rectum of the horses where possible) were performed
by the resident farm veterinarians in the presence of the
authors.
In the first trial conducted on Farm A, 30 weanlings (aged
7–8 months; male = 12; female = 18) were selected and
randomly divided into six groups (5 animals in each group)
after fulfilling the inclusion criteria as outlined above. Five
groups were treated with a single or a combination of

Faecal egg counts

Faecal egg counts were carried out within 48 to 96 h of collection of faeces using the Modified McMaster technique
[30]. Briefly, 4 g of faeces was mixed with 4 ml of water to

Table 1 Details of anthelmintic drugs used in this study
Group

Trial(s) Drugs

Farm A 1
1

®

AMMO Rotational Wormer (Ceva Animal Health Pty
Ltd, Glenorie, NSW, Australia)

MecWorma & Bot® (International Animal Health Prod‑
ucts, Huntingwood, NSW, Australia)

Active ingredient

Dose (per kg body weight)

Oxfendazole (OFZ)

10 mg

Abamectin (ABM)

0.2 mg

1, 2

Strategy-T® (Virbac Australia Pty Ltd, Peakhurst, NSW,
Australia)

Oxfendazole and pyrantel (OFZ + PYR)

1, 2

Equest® Plus Tape (Zoetis Australia Pty Ltd, Rhodes,
NSW, Australia)

10 mg oxfenda‑
zole + 6.6 mg pyrantel
base

Moxidectin and praziquantel (MOX + PZQ)

0.4 mg

1

MecWorma & Tape® (International Animal Health
Products)

Abamectin and morantel tartrate (ABM + MOR) 54 mg

2

AMMO Allwormer Wormer® (Ceva Animal Health Pty
Ltd)

Abamectin and morantel tartrate (ABM + MOR) 54 mg

1, 2

Untreated control

Equest® Plus Tape (Zoetis Australia, Pty Ltd)

–

Untreated control

–

Farm B 1, 2
1, 2

Moxidectin and praziquantel (MOX + PZQ)

0.4 mg
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make a homogeneous slurry which was then mixed with
52 ml of sucrose solution (specific gravity = 1.27; www.
csrsugar.com.au) and homogenised using a spatula. Following homogenisation, a sample (volume = 1 ml) was pipetted into two chambers of a Whitlock egg counting slide
(www.whitlock.com.au). After 10 min, eggs were counted
using a compound light microscope. A multiplication factor of 15 for this method was applied to calculate the number of eggs per gram.
FEC reduction test and ERP

The percentage FEC reduction (%FECR) was calculated
each week to assess the efficacy of the anthelmintics tested,
and resistance to a particular anthelmintic was declared as
per the guidelines of the American Association of Equine
Practitioners (AAEP) [31]. Briefly, group-based %FECR
was calculated (utilising the equation below) using the
arithmetic group mean FECs at pre-treatment and 2 weeks
post-treatment to declare the efficacy of an anthelmintic in
the group. The %FECR for each treatment group along with
95% uncertainty interval was also analysed using the Bayesian hierarchical model in an online web interface [32]:

FECR% =
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was extracted from pre- and post-treatment pooled faecal samples from each treated and untreated group using
the DNeasy PowerSoil Pro Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. PCRs
were performed in a final volume of 25 µl using the
Strongylus genus-specific primers NC4_F (5′-TGAAAT
TKGAACGAAT-3′) and NC2_R (5′- TTAGTTCTTTTC
CTCCGCT-3′) in a T100 thermal cycler (BioRad Laboratories, Hercules, CA, USA) using the same conditions
as described by Campbell et al. [35]. Known positive
(genomic DNA of Strongylus edentatus) and negative
(Milli-Q H2O) controls were included in each PCR run.
Aliquots (5 μl) of individual amplicons were analysed
on 1.5% (w/v) agarose gels in Tris–Borate–EDTA buffer,
stained with GelRed (Biotium, Fremont, CA, USA) and
visualised using a GelDoc system (BioRad Laboratories).

Results
Anthelmintic efficacy

The weanlings on Farm A had pre-treatment FECs of
cyathostomins ranging from 150 to 2730 EPG and from
45 to 630 EPG for the first and second trials, respectively.

EPG(pre − treatment) − EPG(post − treatment)
× 100
EPG(pre − treatment)

Given that equine-specific criteria are yet to be established to define the presence of resistance to individual
MLs and drug combinations, an efficacy of %FECR
of > 95% for MLs/drug combinations and > 90% for BZs/
THPs was used. Additionally, 95% lower confidence limits (LCLs) of 90% and 80% were selected for classifying
resistance to MLs/drug combinations and BZs/THPs,
respectively, as per the guidelines of the World Association for the Advancement of Veterinary Parasitology
(WAAVP) [33]. The 95% confidence intervals were calculated based on the delta method as described by Levecke et al. [34]. Resistance to a particular anthelmintic
was confirmed if it failed to meet both thresholds, while
a result where only one of the two criteria was met was
considered to be suspected resistance. Likewise, there is
no consensus on the calculation/interpretation of ERP in
horses and no guidelines exist for setting a cut-off for the
ERP of combination products. For this study, we adopted
the standard where ERP is defined as the time elapsed
from day 0 to when %FECR returns to < 90% [16].
Use of PCR for nematode identification

In order to rule out the presence of large strongyles
(i.e. Strongylus spp.), a PCR targeting the second internal transcribed spacer (ITS-2) of the nuclear ribosomal
DNA was performed as described previously [35]. DNA

In the first trial, resistance to OFZ (− 41% FECR; − 195%
LCL), ABM (73% FECR; 60% LCL) and OFZ + PYR (82%
FECR; 66% LCL) was observed 2 weeks post-treatment
(Fig. 1). The %FECR based on Bayesian hierarchical
model analysis using group mean FECs pre- and posttreatment values resulted in the same efficacy as calculated by the method described in the AAEP parasite
control guidelines. However, the former method also
calculated the CI where efficacy was 100% (Table 2). The
FEC of the majority of animals in each treatment group
did not return to 0 EPG even by 1 week post-treatment.
A consistent increase in individual horse EPG was noted
in the following weeks for all anthelmintics tested, with
the exception of MOX and ABM + MOR where cyathostomin eggs reappeared in faeces at ≥ 3 weeks post-treatment (Fig. 2).
On Farm B, the initial FEC of cyathostomins ranged
from 75 to 3480 EPG and from 150 to 1455 EPG for yearlings and weanlings, respectively. Resistance to MOX was
found in both trials, with FECR of 90% (70% LCL) and
89% (82% LCL) 2 weeks post-treatment in the first and
second trials, respectively (Fig. 1).
The FECs of cyathostomins of horses included in the
control group were found to be consistently positive
throughout the study period in both trials, with no sign
of a clinical disease.
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ERP for MOX and ABM + MOR

Out of five anthelmintic products tested in trial one on
Farm A, only MOX and ABM + MOR resulted in 100%
FECR 2 weeks post-treatment; therefore, we determined the
ERP for these two anthelmintic products only. Three weeks

post-treatment, one of the horses in the MOX-treated
group tested positive for cyathostomin eggs; however, the
group %FECR remained high at 99% and 100% for MOX
and ABM + MOR, respectively. Subsequently, the sampling
frequency was reduced to once every 2 weeks during trial 1

Fig. 1 Efficacy of anthelmintics against cyathostomins on Farms A and B, based on 2-weekly post-treatment faecal egg counts. ABM, OFZ and
OFZ + PYR were tested on Farm A while MOX was tested on Farm B. Each circle shows the percentage of the faecal egg count reduction (%FECR)
for each anthelmintic at 2 weeks post-treatment while each horizontal black line shows the upper and lower 95% confidence intervals. Lower
confidence limits of < 0 were considered to be 0. The asterisk indicates the anthelmintic used in the second trial. ABM Abamectin, MOX moxidectin,
OFZ oxfendazole, OFZ + PYR oxfendazole and pyrantel combination

Table 2 Cyathostomin faecal egg counts and percentage faecal egg count reduction at 2 weeks post-treatment with 95% confidence
intervals
Treatment group

Farm

Trial

N*

FECs pretreatment (EPG)

FECs posttreatment (EPG)
week 2

Mean

Range

Mean

Range

N**

%FECR (95% CI) by AAEP
method

− 41 (− 195 to − 57)

%FECR (95% CI) Bayesian
hierarchical model

Oxfendazole

A

1

5

795

165–2730

1122

330–1890

5

Abamectin

A

1

5

774

315–1980

207

0–570

4

Moxidectin

A

1

5

546

240–930

0

– 0

100

100 (98–100)

Abamectin + morantel

A

1

5

561

150–1290

0

– 0

100

100 (98–100)

Oxfendazole + pyrantel

A

1

5

870

150–2235

159

15–225

5

82 (66–92)

Moxidectin

B

1

7

1530

75–3480

148

0–675

5

90 (70–99)

Moxidectin

A

2

5

480

Abamectin + morantel

A

2

5

B

2

5

Moxidectin

150–630

0

162

45–450

0

1041

150–1455

117

75–165

73 (60–84)

0 (0–5)
73 (65–79)

82 (76–86)
90 (88–93)

– 0

100

100 (98–100)

– 0

100

100 (94–100)

5

89 (82–94)

89 (85–92)

AAEP American Association of Equine Practitioners, CI confidence interval, EGP eggs per gram, FEC faecal egg count, FECR faecal egg count reduction, N* number of
horses in group, N** number of horses shedding eggs within a group 2 weeks post-treatment
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due to the labour required for the collection of faecal samples. At 5 weeks post-treatment, a sharp decrease in the efficacies of both MOX and ABM + MOR was observed which
continued into the sixth week (Fig. 3). Hence, the ERP for
both MOX and ABM + MOR was considered to be 5 weeks
in the first trial. In the second trial, post-treatment weekly
%FECR data revealed that the ERP for ABM + MOR and
MOX was 4 and 5 weeks, respectively (Fig. 3).
Identification of parasites

PCR amplicons revealed no band on 1.5% agarose gels in
any of the pre- and post-treatment pooled faecal samples
for all groups of horses while the positive control verified
an expected amplicon size of approximately 370 bp, confirming that infections did not involve large strongyles.

Discussion
This is the first report of resistance in cyathostomins to
ABM. This study not only provides evidence of resistance
in cyathostomins to single anthelmintics (ABM, OFZ
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and MOX) but is the first account of multidrug resistance in cyathostomins to treatment with a combination of anthelmintics (OFZ + PYR) on a single farm. The
observed efficacies of OFZ, ABM, MOX and OFZ + PYR
at 2 weeks post-treatment (− 41%, 73%, 90 and 89% and
82%, respectively), were substantially lower than those
used for declaring AR as outlined in the AAEP guidelines
[31]. However, the efficacies of MOX and ABM + MOR
were 100% at 2 weeks post-treatment in one trial, but
those of both drugs decreased below the ERP cut-off limits within 4–5 weeks post-treatment.
This study presents the first report of AR and markedly reduced ERP for MLs (5 weeks for MOX) and a
drug combination (4 weeks for ABM + MOR) in cyathostomins in Australian horses while the manufacturer
claimed ERP of at least 14 weeks for MOX in Australia
[36]. Previously, only one study has reported reduced
ERP of 6 and 12 weeks for IVM and MOX, respectively,
in cyathostomins [22]. Since the introduction of MOX
formulations for use in horses, reduced efficacy in treating cyathostomins in donkeys was first reported in an

Fig. 2 Weekly faecal egg counts (eggs per gram of faeces) of cyathostomins in individual horses at day 0 up to 6 weeks post-deworming for each
anthelmintic used in both trials 1 and 2 at Farm A. Each circle represents the value of an individual faecal egg count per week
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Fig. 3 The efficacy (%FECR) of MOX and the ABM + MOR combination at Farm A up to 5 and 6 weeks post-treatment in trials 2 and 1, respectively.
The 90% FECR threshold for defining the egg reappearance period is indicated with a black dotted line. The asterisk indicates the anthelmintic used
in the second trial. ABM + MOR Abamectin and morantel combination

abstract published in a conference proceedings [37], in
which the mean %FECR in one of the treatment groups
was 87% and 31% on 14 and 25 days post-treatment,
respectively. However, this lower efficacy could be due
to the off-label use of MOX (formulation for intramuscular use in cattle) which might have affected the pharmacokinetics of the drug [38]. A recent study in Brazilian
military horses reported resistance in cyathostomins to
MOX; however, in this study anthelmintics were administered every 30 to 90 days and the study was started
30 days following the last treatment, with the results
possibly representing a selection bias for MOX-resistant
cyathostomins [39]. In comparison, in our study, MOX
registered for use in horses was used at the recommended
dose rate, and selected horses had not been dewormed in
the 8–10 weeks prior to the start of both trials. However,
resistance to ABM and MOX was confirmed in weanlings and yearlings at the same farms. These resistant
worms could have evolved as a result of intrinsic farm
factors, such as selection pressure, frequent mutation
events resulting in the recurrent appearance of pre-existing alleles in cyathostomins [40] or importation of such
genotypes through the introduction of new horses onto
the farms. Farm A is a large thoroughbred breeding farm
where > 200 mares arrive for breeding each year from
various local and interstate localities. Farm B routinely

imports horses from other countries. Such horizontal
transfer of resistant worms was recently demonstrated
in a study assessing ML efficacy in cyathostomins on a
US horse farm where resistance to IVM and MOX was
detected in cyathostomins in yearlings recently imported
from Ireland, suggesting the importation of resistant
cyathostomins from Ireland to the USA [8].
Among various predisposing factors for the development of AR in cyathostomins in this study, the frequency
of deworming is likely a reason for the resistance to MOX
as this anthelmintic was routinely used on Farm B for
at least 1 year, with an interval of 8–10 weeks between
treatments. In previous studies, the frequent use of
anthelmintics was found to be associated with the development of AR [41, 42]. Another plausible factor for the
development of resistance in cyathostomins to MOX (as
compared to other MLs) is the high efficacy of this drug
against larvae [43–45], minimising refugia and leading to greater selection pressure for resistant worms. A
recent simulation-based study found that climate, season and the number of treatments per year were key factors favouring the development of AR in cyathostomins
[42]. Given Australia’s diverse climatic zones with profound seasonal variations and the recommended interval
for the deworming of horses being common across all
of these zones, larger scale studies are needed to assess
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the prevalence of AR in MLs, such as ABM and MOX,
which are considered the last hope of ‘perceived’ effective
anthelmintics against cyathostomins in horses.
The resistance to OFZ in cyathostomins found in this
study is consistent with the results of previous studies
which report widespread and well-established resistance
patterns in cyathostomins against BZs [6, 46–49]. The
resistance to OFZ might have contributed to the reduced
efficacy of the OFZ + PYR combination (82% FECR) at
2 weeks post-treatment in the current study. Although
resistance was found to both OFZ and OFZ + PYR, the
combination of anthelmintics yielded increased efficacy
compared to OFZ alone. This additive efficacy could be
due to preserved efficacy of PYR which was not tested
alone due to its unavailability in Australia. A similar phenomenon was observed previously by Scare et al. [28]
who reported enhanced efficacy (but still below effective limits: 76.6% FECR) of the OBZ + PYR combination
against cyathostomins whereas the individual anthelmintic efficacies were 66.7% and 63.3%, respectively. However, the maximum efficacy achieved was not sustained
in successive trials, suggesting that combination therapy
against a double resistant cyathostomin population is not
sustainable.
For a timely diagnosis of AR, assessment of ERP is
considered to be an early indicator [5]. In this study, we
found reduced ERP for MOX and ABM + MOR on Farm
A. Shortened ERP for cyathostomins following ML treatments is widely reported in the literature. For example,
an ERP of 4 weeks for cyathostomins following treatment
with MOX has been reported in the USA [50]. Likewise,
a European study reported an ERP of 6–8 weeks after
treatment with MOX [51]. The longer ERP for MOX, in
comparison to other ML drugs, is likely due to greater
efficacy against various developmental stages of cyathostomins. However, in a recent study, the efficacy of MOX
against the immature stages of cyathostomins (late L3/
L4) was reduced, resulting in a decreased ERP [50], with
the development of cross-resistance among MLs possibly
contributing to the reduction in efficacy. The phenomenon of cross-resistance has been shown in Haemonchus contortus (a stomach nematode of sheep and goats),
when rodents were infected with IVM-resistant and
-susceptible strains of the parasite and then treated with
MOX [52]. The authors found that MOX achieved an efficacy of ≤ 47.2% against an IVM-resistant strain at a dose
that invariably killed ≥ 98% of an IVM-susceptible strain,
suggesting that worms resistant to one ML may likely be
resistant to another ML [52]. More recently, resistance
to MOX was found in cyathostomins following confirmation of IVM resistance in a group of imported horses
[8]. The resistance to ABM alone found in the current
study could have not only affected the efficacy of a related
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anthelmintic, i.e. MOX, but possibly also led to reduced
efficacy of ABM + MOR on Farm A.
Although the efficacies of some anthelmintic products
were re-assessed to ascertain the presence or absence
of resistance, the findings of this study should be interpreted keeping in view possible limitations, such as (i)
a small number of horses per treatment group and (ii) a
low FEC threshold for the selection of animals. Furthermore, owing to the unavailability of single formulations
of MOR and PYR for equines in Australia, we only tested
available combinations of these drugs. Therefore, future
studies should test the efficacy of single anthelmintics
along with combinations, where available, using larger
numbers of animals per treatment group and a higher
FEC threshold.

Conclusion
This study provides the first report of resistance to ABM,
MOX and a combination of anthelmintics in cyathostomins. MOX is arguably the last effective anthelmintic
to manage cyathostomins in horses; however resistance
was detected on more than one occasion in this study. The
detection of cyathostomin resistance and/or reduced ERP
to MLs (when used as a single anthelmintic and in combination) are concerning, and warrant the use of alternative
worm control strategies. Further field studies involving a
greater number of horses per group are required to assess
the prevalence of resistance to single and multiple anthelmintics in cyathostomin populations. Consensus on FECbased methods and interpretation of the detection of
reduced drug efficacy/resistance, i.e. FECRT and ERP, are
required to facilitate the monitoring, reporting and comparison of data between studies.
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